- Study Suggests Earlier Is Better for Heart Valve Replacement Procedures
- Bird Flu Infection Confirmed in a Pig for First Time in U.S.
- Election Fears Are Keeping Americans Awake at Night, Survey Shows
- Most Patients Can Keep Using GLP-1 Weight Loss Meds Before Surgeries
- When This Black Cat Crossed His Path, It Was a Lucky Day for Medicine
- Staying In: Did Pandemic Shift Americans’ Leisure-Time Habits Permanently?
- Costs for MS, Parkinson’s and Alzheimer’s Meds Keep Rising
- With Cases Rising, What You Need to Know About Whooping Cough
- Halloween Candy: Don’t Get Spooked by All That Sugar
- Check Your Cabinet: Some COVID Test Expiration Dates Have Been Extended, FDA Says
Aristada Approved for Schizophrenia
Aristada (aripiprazole lauroxil) extended release injection has been approved by the U.S. Food and Drug Administration to treat the disabling brain disorder schizophrenia, the agency said Tuesday in a news release.
Schizophrenia, affecting about one percent of Americans, typically has symptoms including hearing voices that aren’t real, believing other people are controlling one’s mind or thoughts, and paranoia. Symptoms are commonly first seen among people under age 30.
Aristada’s effectiveness was demonstrated in a 12-week clinical study involving 622 people. As with other drugs in this class, known as “atypical antipsychotics,” the medication includes a boxed warning against off-label use that may increase the risk of death among older people with dementia-related psychosis.
The new drug’s most common side effect is the feeling the need to move constantly, medically called akathisia.
Aristada is manufactured by Alkermes, Inc., based in Waltham, Mass.
More information
To learn more, visit the FDA.
Source: HealthDay
Copyright © 2024 HealthDay. All rights reserved.